Our Pipeline
Gandeeva’s proprietary platform leverages artificial intelligence, machine learning, and high-resolution molecular imaging to enable our team to predict and drug transient protein-protein interactions for therapeutic benefit. Our strategy allows us to discover drugs against previously inaccessible targets in oncology with unmet medical needs.
Discovery & Optimization
IND-Enabling
Phase 1/2
GND-323
MAPK pathway
Development candidate selected
Discovery
IND-Enabling
Phase 1/2
GND-02
Gain-of-function iGlue™
Lead optimization ongoing
Discovery
IND-Enabling
Phase 1/2
GND-03
Inhibitory iGlue™
Hit validation ongoing
Discovery
IND-Enabling
Phase 1/2
GND-04
iGlue™
Target validation ongoing
Discovery
IND-Enabling
Phase 1/2
Partnering
Our mission is to transform the lives of patients through the development of highly targeted, first-in-class therapeutics. We are open to the exploration of opportunities to expand our programs, from in-house development to collaborative research, and invite potential partners to contact us.
